Amlodipine / olmesartan Side Effects
Not all side effects for amlodipine / olmesartan may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to amlodipine / olmesartan: oral tablet
In addition to its needed effects, some unwanted effects may be caused by amlodipine / olmesartan. In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking amlodipine / olmesartan:More common
- Bloating or swelling of the face, arms, hands, lower legs, or feet
- rapid weight gain
- Fast, irregular, pounding, or racing heartbeat or pulse
- unusual tiredness or weakness
- Abdominal or stomach pain
- dark urine
- decreased urine output
- itching skin or rash
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- light-colored stools
- muscle pain or stiffness
- upper right abdominal or stomach pain
- yellow eyes or skin
Some of the side effects that can occur with amlodipine / olmesartan may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:Less common
- feeling of warmth
- redness of the face, neck, arms, and occasionally, upper chest
- sleepiness or unusual drowsiness
- Hives or welts
- redness of the skin
For Healthcare Professionals
Applies to amlodipine / olmesartan: oral tablet
Cardiovascular side effects associated with amlodipine are dose-related, are usually the result of vasodilation, and include flushing in less than 1% and peripheral edema in 2% of patients. Peripheral edema may become a chronic problem, and has occurred in up to 10% of patients who are receiving 10 mg doses. Palpitations occur in 1% to 5% of patients. Recent data have shown that the use of amlodipine in patients with NYHA Class III or IV heart failure is not associated with worsened heart failure. Bradycardia, hypotension, and syncope have been reported in less than 1% of patients. Generalized edema has also been reported rarely.
Cardiovascular side effects associated with olmesartan including tachycardia, chest pain, and peripheral edema have been reported in 0.5% to 1% of patients. At least 5 cases of facial edema and at least one case of olmesartan-induced angioedema, which resolved over 7 to 10 days after discontinuing olmesartan, have been reported.
Worsened angina has been rarely associated with the use of amlodipine (as with other calcium channel blockers).
A case study reports a 34-year-old woman with a history of chronic renal failure secondary to glomerulonephritis, who was started on amlodipine for uncontrolled hypertension. Three days later the patient developed severe thrombocytopenia. After discontinuation of the drug, the platelet count returned to normal.
Hematologic side effects associated with amlodipine have included isolated cases of thrombocytopenia.
Hematologic side effects associated with olmesartan have included decreased hemoglobin and hematocrit.
Nervous system side effects associated with amlodipine have included headache (8%), dizziness (3%), and fatigue (5%). Vertigo, tremors, and paresthesias have been reported in less than 1% of patients receiving amlodipine.
Nervous system side effects associated with olmesartan have included dizziness (3% vs. 1% with placebo), vertigo (0.5% to 1% with placebo), and insomnia (0.5% to 1% with placebo). Asthenia has been reported in postmarketing experience.
Respiratory side effects associated with olmesartan have included cough (0.9% vs. 0.7% with placebo), bronchitis, rhinitis, pharyngitis, sinusitis, and upper respiratory tract infection.
Hepatic side effects including jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis) have been reported with amlodipine use. In some instances, these cases were severe enough to require hospitalization.
Hepatic side effects associated with olmesartan have rarely included liver enzyme and serum bilirubin elevations.
Metabolic side effects associated with olmesartan have included hyperglycemia and hypertriglyceridemia.
Hypersensitivity reactions have rarely been reported, although experience with amlodipine is limited. A single case of erythema multiforme during amlodipine therapy has been reported.
Hypersensitivity side effects including rare cases of angioedema have been reported in patients receiving olmesartan.
Hypersensitivity reactions reported postmarketing have included anaphylactic reactions and peripheral edema.
A 62-year-old man with hypertension and psoriasis developed erythema multiforme within three days after starting amlodipine. The rash resolved upon substitution with nifedipine.
Calcium channel blockers have been suggested as possibly unsafe in patients with acute porphyria.
Other side effects including a single case of acute porphyria exacerbation have been associated with the use of amlodipine, and confirmed upon rechallenge in the same patient.
Renal side effects have been reported rarely with amlodipine use. At least one case of interstitial nephritis has been associated with amlodipine therapy.
Renal side effects associated with ACE inhibitors have included increases in serum creatinine or BUN in patients with renal artery stenosis. Acute renal failure and increased serum creatinine levels have been reported in postmarketing experience.
Musculoskeletal side effects including arthralgia, arthritis, myalgia, and skeletal pain have been reported in 0.5% to 1% of patients receiving olmesartan. Rhabdomyolysis has been reported during postmarketing experience in patients receiving angiotensin II receptor blockers.
Gastrointestinal side effects including nausea have been associated with amlodipine in 3% of patients.
Gastrointestinal side effects including abdominal pain, dyspepsia, gastroenteritis, and nausea have been reported in 0.5% to 1% of patients receiving olmesartan. Vomiting has been reported in postmarketing experience. Diarrhea has been reported in more than 1% of patients but at the same or greater incidence than placebo.
Anorexia, constipation, dyspepsia, vomiting, flatulence, and diarrhea have been reported in less than 1% of patients. As with some other calcium channel blockers, rare cases of gingival hyperplasia have been associated with amlodipine. At least one case of amlodipine-associated dysgeusia has been reported and confirmed upon rechallenge.
Dermatologic side effects including amlodipine-associated lichen planus and telangiectasia have been rarely reported.
Dermatologic side effects associated with olmesartan have included rash (0.5% to 1%), alopecia, pruritus, and urticaria.
The patient's gynecomastia resolved upon substitution of amlodipine with an unrelated antihypertensive agent. The use of amlodipine has not been associated with adverse effects on glucose metabolism or serum lipids.
Endocrine side effects including a single case of gynecomastia have been associated with the use of amlodipine.
Genitourinary side effects including gynecomastia have been reported in postmarketing experience with amlodipine.
Genitourinary side effects including urinary tract infection have been reported in 0.5% to 1% of patients receiving olmesartan. Hematuria has been reported in more than 1% of patients but at the same or greater incidence than placebo.
More about amlodipine/olmesartan
- Other brands: Azor
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.